Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:08:30.856Z.
Calculation as of: 2026-10-06T21:08:30.856Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d4773eeabafa62aebeff6315a1128d32b86b9098e0544dfe9acdb21c4fcfe70f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$153.58M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.64M
EV/EBIT Ratio
N/A
TTM Avg
18.14x
3Y Avg
8.57x
5Y Avg
7.17x
Market Cap
$159.14M
EV/EBIT Ratio
N/A
TTM Avg
8.53x
3Y Avg
141.14x
5Y Avg
141.14x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $153.79M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | N/A | 189.93x | 95.49x | 94.46x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | N/A | 18.14x | 8.57x | 7.17x |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | N/A | 8.53x | 141.14x | 141.14x |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A | 1490.94x | 1490.94x | 1490.94x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
